
Isabl
Isabl is a YC Winter 2020 (W20) company. Based in New York, NY, USA; Remote. Team of 5.
About Isabl
Summary
Isabl builds whole-genome and transcriptome sequencing software for cancer diagnostics, replacing narrow panel-based genetic tests that examine only a handful of mutations. Oncology labs run a tumor biopsy through a sequencer and Isabl's platform analyzes the complete genome and transcriptome, surfacing every cancer-associated mutation in the sample. This gives clinicians and researchers a fuller picture of tumor biology to guide treatment decisions, disease surveillance, and biomarker discovery.
Business model
SaaS fee for access to the whole-genome and transcriptome sequencing analysis platform (WGTS SaaS)
Go-to-market
Isabl targets cancer genomics labs, molecular diagnostic teams, and oncology researchers; prospective customers engage through a scheduled meeting with the sales team.
From the Y Combinator listing
Cancer tests based on whole genome and transcriptome data.
Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.
Facts
- Healthcare / Healthcare -> Diagnostics
- New York, NY, USA; Remote
- 5
- Active
- Early
Founders (3)
- Andrew Kung
- Elli Papaemmanuil
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works